AbbVie Soothes Safety Fears With More Upadacitinib RA Data
Following the fifth positive pivotal trial for AbbVie's JAK1 inhibitor in rheumatoid arthritis, it is looking increasingly likely that upadacitinib is going to be approved next year, although the company is hoping robust safety data mean that it will not get a black box warning similar to the one issued by the FDA for Lilly's recently approved same-class rival Olumiant.
You may also be interested in...
AbbVie Ups The Ante For Upadacitinib At EULAR
With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms of rheumatoid arthritis to achieving remission.
Mortality Signal For Pfizer's Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class
Analyst speculates that risk of pulmonary embolism for a higher unapproved dose of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Keeping Track: US FDA Receives Submissions Galore As Year Ends
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.